 |
|
|
|
|
| Que sont les EUROCONFERENCES ? | |
| What are the EUROCONFERENCES ? | |
| EUROCONFERENCES passées | |
 |
|
Gene and cell therapy
Thérapie génique et cellulaire
Modifying the fate of human embryonic stem cells
Peter W. Andrews, University of Sheffield, UK
Human embryonic stem cells - a potential platform for cell and gene therapy of the CNS
Peter W. Andrews, University of Sheffield, UK
Human embryonic stem cells - a potential platform for cell and gene therapy of the CNS
Benjamin E. Reubinoff, Hadassah University Medical Center, Jerusalem, Israel
Genetic marking studies in non-human primates: Insights into hematopoiesis and leukemogenesis
Cynthia E. Dunbar, National Institutes of Health, Bethesda, USA
Gene therapy of Severe Combined Immunodeficiencies (SCID)
Alain Fischer, Inserm U429, Hôpital Necker-Enfants Malades, Paris, France
Gene therapy for severe combined immunodeficiency
Adrian J. Thrasher, Institute of Child Health, London, UK
Gene therapy of ADA-deficient SCID
Alessandro Aiuti, San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milano, Italy
Gene therapy of chronic granulomatous disease
Manuel Grez, Institute for Biomedical Research, Georg-Speyer-Haus, Frankfurt, Germany
Approaches to the gene therapy of the b-hemoglobinopathies
Philippe Leboulch, Harvard Medical School, Boston, USA
Gene therapy in the skeletal muscle
Olivier Danos, CNRS UMR 8115, Généthon, Evry, France
Mesoangioblasts for the cell therapy of muscular dystrophies
Giulio Cossu, Stem Cell Research Institute, HSR, Milano, Italy
Retinal degenerations: from cell therapy to cell signalling; pre-clinical and clinical issues
José-Alain Sahel, Inserm U592, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France
Gene and cell therapy in critical leg ischemia
Joseph Emmerich, Inserm U428, Université Paris 5, France
Correction of neuropathology in the dog model of Hurler syndrome
Jean-Michel Heard, Inserm U622, Institut Pasteur, Paris, France
Transfer and reprogramming of neural stem cells in spinal cord injury
Lars Olson, Karolinska Institutet, Stockholm, Sweden
Hematopoietic stem cell gene therapy for X-linked adrenoleukodystrophy using an HIV-derived lentiviral vector
Nathalie Cartier-Lacave, Inserm U561, Hôpital Saint Vincent de Paul, Paris, France
Specificity of retroviral DNA integration
John M. Coffin, Tufts University, Boston, USA
Control of retroviral DNA integration by cellular factors
Frederic Bushman, University of Pennsylvania, Philadelphia, USA
Integrating vector systems - Challenges to basic, preclinical and clinical development
Christof v. Kalle, Cincinnati Children's Hospital Research Foundation, USA
Modulation of transgene immune response is a requirement for successful gene therapy trials
Maria Grazia Roncarolo, San Raffaele Telethon Institute For Gene Therapy (HSR-TIGET), Milano, Italy
Cynthia E. Dunbar, National Institutes of Health, Bethesda, USA
Gene therapy of Severe Combined Immunodeficiencies (SCID)
Alain Fischer, Inserm U429, Hôpital Necker-Enfants Malades, Paris, France
Gene therapy for severe combined immunodeficiency
Adrian J. Thrasher, Institute of Child Health, London, UK
Gene therapy of ADA-deficient SCID
Alessandro Aiuti, San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milano, Italy
Gene therapy of chronic granulomatous disease
Manuel Grez, Institute for Biomedical Research, Georg-Speyer-Haus, Frankfurt, Germany
Approaches to the gene therapy of the b-hemoglobinopathies
Philippe Leboulch, Harvard Medical School, Boston, USA
Gene therapy in the skeletal muscle
Olivier Danos, CNRS UMR 8115, Généthon, Evry, France
Mesoangioblasts for the cell therapy of muscular dystrophies
Giulio Cossu, Stem Cell Research Institute, HSR, Milano, Italy
Retinal degenerations: from cell therapy to cell signalling; pre-clinical and clinical issues
José-Alain Sahel, Inserm U592, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France
Gene and cell therapy in critical leg ischemia
Joseph Emmerich, Inserm U428, Université Paris 5, France
Correction of neuropathology in the dog model of Hurler syndrome
Jean-Michel Heard, Inserm U622, Institut Pasteur, Paris, France
Transfer and reprogramming of neural stem cells in spinal cord injury
Lars Olson, Karolinska Institutet, Stockholm, Sweden
Hematopoietic stem cell gene therapy for X-linked adrenoleukodystrophy using an HIV-derived lentiviral vector
Nathalie Cartier-Lacave, Inserm U561, Hôpital Saint Vincent de Paul, Paris, France
Specificity of retroviral DNA integration
John M. Coffin, Tufts University, Boston, USA
Control of retroviral DNA integration by cellular factors
Frederic Bushman, University of Pennsylvania, Philadelphia, USA
Integrating vector systems - Challenges to basic, preclinical and clinical development
Christof v. Kalle, Cincinnati Children's Hospital Research Foundation, USA
Modulation of transgene immune response is a requirement for successful gene therapy trials
Maria Grazia Roncarolo, San Raffaele Telethon Institute For Gene Therapy (HSR-TIGET), Milano, Italy
Frédéric Pâques, Cellectis S.A., Romainville, France
Genome editing: its promise and limitations for gene therapy
Brian R. Davies, Institute for Inherited Disease Research, Newtown, USA
New developments in lentiviral vectors
Jacques Mallet, CNRS UMR 7091, Hôpital de la Pitié-Salpétrière, Paris, France
Philosophical and anthropological queries about gene/cell therapy
Genome editing: its promise and limitations for gene therapy
Brian R. Davies, Institute for Inherited Disease Research, Newtown, USA
New developments in lentiviral vectors
Jacques Mallet, CNRS UMR 7091, Hôpital de la Pitié-Salpétrière, Paris, France
Philosophical and anthropological queries about gene/cell therapy
Anne Fagot-Largeault, Collège de France, Paris, France